Form 4: Atea Pharmaceuticals Director Howard Berman Granted 164,800 Stock Options

Atea Pharmaceuticals, Inc. Director Howard Berman was granted 164,800 stock options with an exercise price of $3.25, vesting over three years.

Summary

• Howard Berman, a Director of Atea Pharmaceuticals, Inc. (AVIR), was granted 164,800 stock options.
• The stock options have an exercise price of $3.25 per share.
• The options will vest in thirty-six (36) equal monthly installments following June 20, 2025, becoming fully vested on June 20, 2028.
• The expiration date for these stock options is June 19, 2035.
• Following this reported transaction, Mr. Berman beneficially owns 164,800 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns management's interests with shareholders, but it is a routine compensation matter rather than a significant operational or financial announcement.

Positives

• The grant of stock options to Director Howard Berman aligns his financial interests with those of the company's shareholders, incentivizing long-term value creation.
• The three-year vesting schedule encourages sustained commitment and performance from the director.

Future Outlook

This Form 4 filing is a transactional report and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

The grant of stock options to directors is a common practice across various industries, including pharmaceuticals, as a form of long-term incentive compensation. It aims to align the interests of the board members with the company's performance and shareholder value. This specific transaction is a routine compensation event for a director.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a standard compensation practice for directors in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.
• While specific grant sizes and exercise prices vary based on company size, performance, and individual roles, this type of equity incentive is widely used to attract and retain talent and align interests.
• No specific comparable companies, projects, or results are mentioned in this filing to allow for a direct quantitative comparison.

Related Party Transactions

• The grant of stock options to Howard Berman, a Director, constitutes a related party transaction as it involves compensation from the company to a member of its board. This is a standard and disclosed form of related party dealing.

Stakeholder Impact

• Shareholders: Potentially positive, as the option grant aligns the director's financial incentives with the long-term performance of the company, encouraging decisions that enhance shareholder value.

Next Steps

• The stock options will vest in 36 equal monthly installments starting June 20, 2025.
• The options will be fully vested by June 20, 2028.
• The options can be exercised at any time after vesting until their expiration on June 19, 2035.

Key Dates

Keywords

Atea Pharmaceuticals, AVIR, Howard Berman, Director, Stock Option, Insider Transaction, Compensation, Equity Grant, SEC Form 4